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Abstract: 
A number of recent studies have highlighted the role of axonal transport in the 
pathogenesis of motor neuron diseases. Mutations in genes that control 
microtubule regulation and dynamics have been shown to cause motor 
neuron degeneration in mice and in a form of human motor neuron disease. In 
addition, mutations in the molecular motors dynein and kinesins and several 
proteins associated with the membranes of intracellular vesicles that undergo 
transport cause motor neuron degeneration in humans and mice. 
Paradoxically, evidence from studies on the legs at odd angles mouse (Loa) 
and a transgenic mouse model for human motor neuron disease suggest that 
partial limitation of the function of dynein may in fact lead to improved axonal 
transport in the transgenic mouse leading to delayed disease onset and 
increased life span.  
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AXONAL TRANSPORT IN MOTOR NEURONS 
Motor neurons are highly specialised cells with volumes of up to 5,000 times 
larger than the volume of an average cell. Their axons can be more than a 
meter long in the humans and each motor neuron forms many synapses with 
other neurons and muscle cells. These properties of motor neurons and their 
high energy throughput necessitate a highly efficient and finely tuned 
transport system for the delivery of organelles, such as mitochondria and 
endosomes, as well as structural and signalling proteins into the axons and 
for transporting neurotrophic factors from the axon termini to the perikaryon. 
The major components of this transport system are a group of specialised 
motor proteins plus the cytoskeletal networks of microtubules and actin 
filaments. Motor proteins use these networks as intracellular tracks for 
transporting their cargos. 
 
As part of their cytoskeleton neurons also contain neurofilaments which are 
comprised of the neurofilament triplet proteins neurofilament light chain (NF-
L), middle chain (NF-M), and heavy chain (NF-H). Other neuronal 
intermediate filaments include α-internexin and peripherin. Neurofilaments are 
the major intermediate filaments in most terminally differentiated neurones 
whereas α-internexin is expressed more abundantly in the developing 
nervous system (Fliegner et al. 1994; Kaplan et al. 1990), and peripherin is 
expressed mostly in autonomic nerves and sensory neurons (Escurat et al. 
1990; Parysek and Goldman 1988; Troy et al. 1990). The speed of 
conductivity of an impulse down the axon is in part proportional to its calibre 
and an important function of neurofilaments is to control axonal calibre. Thus 
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neurofilaments are particularly abundant in neurones with large-diameter 
axons including those of motor neurones where fast impulse conduction 
velocities are crucial for proper functioning. 
 
Actin filaments are highly enriched in the cell cortex, whereas microtubules 
and neurofilaments run the length of the neurons. Of these the actin filaments 
and microtubules are directly involved in axonal transport. Microtubules are 
long filaments formed by the polymerisation of tubulin dimers consisting of 
one α- and one β- tubulin polypeptides. The α- and β- tubulins are members 
of the same protein family with up to 40% sequence homology and they are 
also highly conserved across species (Cleveland and Sullivan 1985). The 
regular orientation of these tubulin heterodimers confers a structural polarity 
to the microtubules so that one end – the plus end – is the preferred end for 
addition of tubulin dimers  whereas the other end – the minus end – grows 
more slowly under physiological concentrations of tubulin.  A third member of 
the tubulin family is γ-tubulin which is found at microtubule organising centres 
(MTOC) and it is thought to be involved in nucleation of microtubules and 
anchoring the minus-end (Joshi 1993).  
 
In the axons microtubules form long, but not continuous, filaments which have 
a uniform polarity with the plus-end directed away from the cell body, whereas 
in the dentrites they are generally shorter and they are non-uniform with 
respect to polarity (Baas et al. 1988). As a result of their association with 
various microtubule associated-proteins (MAPs), microtubules in the axons 
and dendrites are much more stable than those in most interphase cells. In 
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addition, MAPs contribute to the composition of a network of filamentous 
structures that cross-link microtubules in the neurites and owing to the 
difference between the composition of the MAPs in axons and dendrites the 
spacing between microtubules in axons (~20 nm) differs from that in the 
dendrites (~65 nm) (Hirokawa 1982; Hirokawa and Takemura 2005). This is 
achieved partly by selective transport and stabilisation of tau (a microtubule 
associated protein) in axons and MAP2 in dendrites (Hirokawa et al. 1996; 
Kanai and Hirokawa 1995; Okabe and Hirokawa 1989). Moreover, 
microtubule dynamics and remodelling in neurons are crucial for the 
extension, arborisation, and guidance of the axons. These processes are 
regulated by the functions of MAPs and other enzymes that take part in the 
stabilisation and breakdown of the microtubules (Siegel 1999). 
 
 
Cytoplasmic dynein, kinesin, and unconventional myosin families are the 
molecular motors that use microtubules and actin filaments as tracks for 
intracellular transport within neurons. These motors are structurally similar 
and they all have a globular domain (the head) which forms their motor unit 
and a rod shaped domain (the tail) involved in cargo binding. The head 
domains in dynein and kinesins contain microtubule binding domains. 
Myosins on the other hand have actin binding domains - although there is 
evidence that some unconventional myosins interact with microtubules too 
(Cao et al. 2004; Weber et al. 2004). It is through these domains that the 
motor proteins bind to microtubules or actin filaments and by hydrolysing ATP 
generate energy to slide along these tracks. 
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 Miki et al identified 45 genes that belong to the kinesin superfamily in mice 
and humans (Miki et al. 2001). They classified the 45 kinesins into three 
types, based on the position of the motor domain in the protein, as amino 
terminal motor (N-kinesins),  middle motor (M-kinesins), and carboxy terminal 
motor (C-kinesins) types.  The motor domain in the kinesin superfamily is 
highly conserved but there is significant divergence in their cargo binding 
domains, conferring diverse binding properties for binding of a wide range of 
cargo.  In contrast to kinesins, cytoplasmic dynein is encoded by two genes 
with DNCHC1 coding for the majority of the cytoplasmic dynein in neurons. 
The cargo binding diversity of cytoplasmic dynein comes about by the 
heterogeneity of the auxiliary subunits that bind to the tail of this protein. 
 
The net directions of dynein and kinesin movements are defined by the 
plus/minus end polarity of microtubules. N-kinesins and M-kinesins generally 
move towards the plus end and C-kinesins appear to move towards the minus 
end of the microtubules (Hirokawa and Takemura 2005). Cytoplasmic dynein 
on the other hand is classified as a motor protein that moves towards the 
minus-end. Although Ross et al have recently shown that this protein indeed 
moves in both directions along the microtubules (Ross et al. 2006). Their 
study revealed that 30% of the processive runs of single dynein-dynactin 
complexes were directed towards the microtubule plus ends. However, the 
net movements of dynein-dynactin complexes were towards the minus-end in 
both frequency and run length (Ross et al. 2006).  
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Like microtubules actin filaments are also polar with the plus end being more 
dynamic. But unlike microtubules, actin filaments are randomly orientated and 
form shorter filaments. Unconventional myosins such as Myosin V bind to 
these filaments and move toward the plus end.  
 
AXONAL TRANSPORT AND MOTOR NEURON DISEASE 
Motor neuron diseases (MND) constitute several groups of heterogeneous 
disorders that affect adults as well as children. These disorders include spinal 
muscular atrophy (SMA), hereditary spastic paraplegias (HSPs), and 
amyotrophic lateral sclerosis (ALS). Below we will describe the current 
understanding of the disease mechanisms in some of these disorders in 
relation to the axonal transport system (summarised in table 1 and figure 1). 
We will first discuss motor neuron diseases that are caused by impairment of 
microtubule dynamics and compromised vesicle trafficking, then we will 
address mutations in motor proteins, which lead to motor neuron 
degeneration. Finally, we will discuss the extensively researched mutant 
superoxide dismutase 1 (SOD1) that causes familial ALS, focusing on the 
impairment of the axonal transport as an important factor in the pathology of 
ALS. 
 
Microtubule dynamics and MND  
As mentioned above a highly efficient microtubule mediated communication 
system is essential for the proper functioning and health of the motor neurons 
and thus any compromise in the microtubule assembly and dynamics could 
have deleterious consequences for these cells. This has been highlighted by 
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the identification of the causal mutation in the progressive motor neuropathy 
(pmn) mouse. The pmn is an autosomal recessive trait in the mouse, which is 
characterised by progressive caudio-cranial degeneration of the motor axons 
from two-weeks of age followed by death by the age of 4 – 6 weeks. 
Phenotypically pmn resembles the recessive proximal childhood form of 
spinal muscular atrophy (SMA).  A missense point mutation, resulting in a 
W524G substitution, in the gene encoding the tubulin-specific chaperone E 
(Tbce) has been shown to be responsible for pmn (Bommel et al. 2002; Martin 
et al. 2002). The TBCE protein appears to be ubiquitously expressed in the 
nervous system and other organs, with no selectivity for the spinal cord 
(Bommel et al. 2002). It binds to α-tubulin and mediates the assembly of α−β 
heterodimers in the tubulin folding pathway (figure 1). In pmn mice, however, 
the W524G mutation seems to make the protein significantly less stable than 
its wild-type counterpart (Martin et al. 2002). The molecular mechanisms of 
motor neuron degeneration in pmn are not fully understood yet, but the 
selective vulnerability of motor neurons in pmn mice may reflect the highly 
sensitive nature of this group of neurons to any disturbance in the 
components of the axonal transport system.  
 
Impaired microtubule dynamics has also been implicated in a form of 
hereditary spastic paraplegia (SPG4). The HSPs are a clinically and 
genetically heterogeneous group of motor neuron diseases that are 
characterised by progressive lower limb spastic paralysis. This group of 
diseases are conventionally divided into pure and complicated subgroups 
based on absence or presence of additional neurological or non-neurological 
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clinical features (Reid 2003). Pure HSPs are the most common forms of the 
disease and they are histopathologically characterized by the “dying back” of 
the terminal ends of the corticospinal tract axons, usually with longest axon 
being involved first. At least 20 genes are thought to be involved in HSPs and 
of those the most important gene in empidemiolgical terms is SPG4. 
Mutations in SPG4 cause an autosomal dominant form of the disease and 
they are responsible for approximately 40-50% of pure HSPs. The SPG4 
gene product is the microtubule interacting protein spastin (Hazan et al. 
1999). Spastin is ubiquitously expressed in all tissues but with slightly higher 
expression in the foetal brain and it is thought to be a microtubule severing 
protein involved in axon development and maintenance (figure 1). 
 
In their analysis of the role of spastin in neuronal development using zebrafish 
embyo as a model system Wood et al have shown that reducing the function 
of the zebrafish ortholog of spastin by antisense oligonucleotides significantly 
impairs motor axon outgrowth and enhances apoptosis throughout the CNS 
(Wood et al. 2006). They also observed abnormal neuronal connectivity 
throughout the spinal cord (Wood et al. 2006). Mutations in spastin typically 
cause adult-onset HSP with the age of onset being widely variable both within 
and among families and evidence suggest that haploinsufficiency is a likely 
pathogenic mechanism in this disease (Burger et al. 2000). However, all 
reported human HSPs with mutations in both spastin alleles (compound 
heterozygotes) have infantile or childhood onset. Data from wood et al  
suggest that a 50% decrease in spastin function is sufficient for near normal 
neuronal development but it would be detrimental in long term axonal 
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maintenance. It is therefore plausible to suggest that the presence of only one 
normal allele leads to late-onset motor neuron disease, whereas less than 
50% spastin activity would result in neurodevelopmental defects causing 
childhood disease  (Wood et al. 2006). 
 
 In a series of yeast-two-hybrid assays using spastin as bait, Reid and 
Sanderson et al identified several proteins that  interact with spastin, including 
CHMP1B and atlastin (Reid et al. 2005; Sanderson et al. 2006). CHMP1B is a 
component of the ESCRT (endosomal sorting complex required for transport)-
III complex which is responsible for vesicle budding, leading to the release of 
a vesicle carrying specific membrane cargo into the interior of the endosomes. 
Atlastin on the other hand is a GTPase protein and evidence suggests that it 
is localised in the Golgi and/or ER membrane (Sanderson et al. 2006). 
Interestingly, mutations in Atlastin have been shown to cause SPG3, another 
form of hereditary spastic paraplegia (Zhao et al. 2001) – see below. In 
addition, Evans et al have independently reported the interaction between 
spastin and atlastin and they have shown that a clinical mutation in atlastin 
prevents its interaction with spastin (Evans et al. 2006). 
 
Given the role of spastin in microtubule regulation and its interaction with 
CHMP1B and atlastin it is possible that spastin has at least two distinct but 
related roles in neurons. One is the regulation of the microtubule dynamics 
and its other role is to be recruited by adaptor membrane proteins to regulate 
membrane trafficking (Sanderson et al. 2006) (figure 1).  
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Membrane-associated proteins and MND 
Atlastin is most abundant in the brain and spinal cord and mutations in this 
gene are responsible for >10% of autosomal dominant pure HSPs and to date 
all reported mutations in this gene show childhood onset (Muglia et al. 2002; 
Zhao et al. 2001). How these mutations affect the function of atlastin and how 
they cause HSP is not clear yet, but based on the sequence homology of this 
protein with dynamins it is possible that like dynamins, atlastin is involved in 
vesicle trafficking events and it may have a role in the distribution and 
maintenance of the mitochondria (Zhao et al. 2001). In addition, spartin the 
gene implicated in Troyer syndrome, which is an autosomal recessive HSP, 
has been shown to localise to mitochondria and interact with microtubules 
(Benashski et al. 1997; Proukakis et al. 2004; Teuchert et al. 2006). Thus it is 
likely that mutations in spartin impair microtubule-mediated trafficking of 
mitochondria and/or mitochondrial function leading to HSP (figure 1). Troyer 
syndrome, like SPG3 and the homozygous or compound heterozygous SPG4,  
is an early childhood disease (OMIM 275900). It would therefore be 
interesting to see whether spartin and atlastin are in the same pathway as 
spastin and whether they have a role in the early development of the axons. 
 
Recently mutations in CHMP2B which like CHMP1B is a component of the 
ESCRT complexes have been reported in two unrelated patients with ALS 
spectrum disorders. One patient showed progressive muscular atrophy and 
the other showed features of ALS-dementia presenting with frontal lobe 
features before developing ALS (Parkinson et al. 2006).  CHMP2B, CHMP1B, 
atlastin, and spartin provide a link between membrane traffic events, axonal 
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transport and motor neuron degeneration (figure 1). This link is further 
strengthened by the finding that a mutation in the vacular-vesicular protein 
sorting factor-54 (VPS54) is responsible for motor neuron degeneration in the 
Wobbler mouse (wr) (Duchen and Strich 1968; Schmitt-John et al. 2005). In 
this mouse motor neurons undergo swelling and vacuolization of cytoplasm, 
with cell body atrophy. The mice typically die by 3 months of age with 
degeneration in the cell bodies of the brainstem and spinal cord, and 
denervation atrophy of skeletal muscle (reviewed by Nicholson et al 
(Nicholson et al. 2000)). The wr mutation confers an autosomal recessive trait 
and it is in the highly conserved residue 967 changing leucine to glutamine in 
the carboxy-terminal region of VPS54 (Schmitt-John et al. 2005). Further 
analyses of this mouse revealed defective axonal transport in the motor 
neurons (Mitsumoto et al. 1990; Mitsumoto et al. 1993).  VPS54 is a 
component of the Golgi-associated-retrograde protein (GARP). Other partners 
of VPS54 in this heterotetrameric complex in Saccharomyces cerevisiae 
include VPS51, VPS52, and VPS53. It is not known how the wr mutation 
leads to motor neuron degeneration, but based on the studies in yeast, a 
likely explanation is that the L967Q mutation in VPS54 impairs the trafficking 
of the early-endosomes (Quenneville et al. 2006) (figure 1). 
 
Perturbed endosomal trafficking has also been highlighted in an autosomal 
recessive juvenile form of motor neuron disease caused by mutations in ALS2 
(OMIM 205100). ALS2 is a guanine nucleotide exchange factor (GEF) which 
through its carboxy-terminal VPS9 domain activates the small GTPase protein 
Rab5. In addition, the VPS9 domain mediates the localization of ALS2 to 
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early-endosomal compartments (Otomo et al. 2003). Preliminary studies 
suggested that the Als2-null mice did not show obvious developmental, 
reproductive or motor abnormalities. However, Hadano et al observed these 
mice through 21 months of age and have recently reported an age-dependent 
slowly progressive loss of cerebellar Purkinje cells in these mice (Hadano et 
al. 2006). The Als2-null mice also exhibited lower motor neuron disturbances 
associated with astrocytosis and microglial cell activation indicating a sub-
clinical condition in these mice (Hadano et al. 2006). In addition, these 
researchers provide further evidence implicating the impairment of the 
endosomal fusion and trafficking in the Als2-null mice. They analysed the 
uptake of epidermal growth factor (EGF) by fibroblasts isolated from these 
mice and showed that although the endocytosis of the EGF receptor per se 
does not require ALS2, the trafficking and fusion of EGF-positive 
endosomes/vesicles in mutant cells were significantly delayed, suggesting 
that ALS2 might regulate the efficiency of these events in the cell (Hadano et 
al. 2006) (figure 1). 
 
Further evidence linking the intracellular membrane proteins to motor neuron 
disease has come from the identification of a missense mutation (P56S) in the 
vesicle-associated membrane protein/synaptobrevin-associated membrane 
protein B (VAPB) in patients with atypical amyotrophic lateral sclerosis 
(ALS8). This is an autosomal dominant adult onset disease characterised by 
fasciculation, cramps and postural tremor (Nishimura et al. 2004). Vesicle 
associated proteins such as VAPB are intracellular membrane proteins that 
associate with microtubules and are involved in membrane transport (figure 
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1). While the wild-type VAPB protein localises predominantly to the 
endoplasmic reticulum, the distribution of its P56S mutant form is dramatically 
disrupted leading to aggregate formation (Nishimura et al. 2004).  
 
Motor proteins and MND 
Kinesins 
The superfamily of kinesin proteins (KIFs) is comprised of 14 families most of 
which form a long filamentous structure with the globular motor domain at one 
end and the cargo binding domain at the other end (reviewed by Miki et al 
(Miki et al. 2001)).  The neuron specific member of the kinesin superfamily 
KIF5A has been implicated in motor neuron disease. Mutations, including a 
missense N256S substitution mutation, in KIF5A cause the autosomal 
dominant pure hereditary spastic paraplegia 10 (SPG10). Asparagine 256 is 
within a loop/helix motif of the motor domain of the protein (Reid et al. 2002). 
Mutations in this region have been shown to disrupt the microtubule binding of 
the motor domain leading to the failure of the microtubule-dependent 
stimulation of the ATPase activity of the kinesin motor (Song and Endow 
1998). Subsequent screening of other SPG10 families have lead to the 
identification of other mutations including R280C, Y279C, and A361V in the 
same microtubule binding motif of the motor domain (Blair et al. 2006; Fichera 
et al. 2004; Lo Giudice et al. 2006). Evidence suggests that KIF5A 
participates in a heterotetrameric complex (Goldstein and Yang 2000).  Thus 
the likely explanation for the autosomal dominant inheritance of SPG10 is a 
dominant-negative effect and/or haploinsufficiency. Both childhood and adult-
onset cases have been reported in SPG10 families and it remains to see 
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whether the early-onset disease correlates with any possible defects in axon 
development. Although data from knockout KIF5A mice show that null KIF5A 
mutants die neonatally and that, compared with control littermates, the spinal 
cord motor neurons appear to have bigger nuclei and cell bodies (Xia et al. 
2003). 
 
Dynein 
Cytoplasmic dynein consists of two homodimerised heavy chains and multiple 
accessory proteins (King 2000). The C-terminal portion of dynein provides the 
force for movement of dynein along microtubules. The N-terminal domain is 
responsible for heavy chain homodimerisation and binding of accessory 
proteins including intermediate, light intermediate, and light chains. Dynactin 
is another complex which interacts with cytoplasmic dynein through dynein 
intermediate chains and regulates its functions. In addition, it acts as an 
adaptor for binding to some of the cargo transported by dynein. Dynactin is 
composed of several subunits including P150Glued and dynamitin (P50) (Vallee 
et al. 2004).  
 
Defects in cytoplasmic dynein have been shown to cause motor neuron 
degeneration in several mouse models. The Legs at odd angles (Loa) and 
Cramping 1 (Cra1) mice, generated in two independent N-ethyl-N-nitrosourea 
(ENU) mutagenesis programmes, manifest progressive locomotor disorders 
with autosomal patterns of inheritance (Hafezparast et al. 2003). Hafezparast 
et al showed that substitution mutations F580Y and Y1055C in the 
cytoplasmic dynein heavy chain in Loa and Cra1 respectively impair 
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retrograde axonal transport leading to motor neuron degeneration. They also 
demonstrated that these mutations perturb neuronal development and 
migration but leave housekeeping functions of cytoplasmic dynein intact 
(Hafezparast et al. 2003). In addition, LaMonte et al have shown that the 
inhibition of dynein-mediated axonal transport, by postnatal over-expression 
of the dynactin component dynamitin, also results in motor neuron 
degeneration (LaMonte et al. 2002). Indeed, a G59S mutation in P150Glued 
subunit of dynactin has been identified in families with slowly progressive 
autosomal dominant forms of motor neuron disease (Munch et al. 2004; Puls 
et al. 2003; Puls et al. 2005). Affected individuals with this mutation develop 
early adulthood vocal fold paralysis which causes breathing difficulty, 
progressive facial weakness, and weakness and atrophy in distal-limb 
muscles (Puls et al. 2003). Studies on the G59S mutation have revealed that 
the mutation is in a highly conserved domain which interacts directly with 
microtubules and the microtubule plus-end protein EB1 (Ligon et al. 2005). 
Subsequently Levy et al have provided evidence that the G59S mutation 
leads to decreased microtubule binding and enhanced dynein and dynactin 
aggregation. This dual effect of the mutation suggests that both toxic gain-of-
function and loss of function may contribute to the degeneration of motor 
neurons in this disease (Levy et al. 2006). 
 
SUPEROXIDE DISMUTASE 1 (SOD1) AND AXONAL TRANSPORT IN MND 
ALS is the most common adult onset form of motor neuron diseases. It is a 
progressive disease that specifically targets the motor neurons in the spinal 
cord, brain stem, and cortex (Mulder et al., 1986; Rowland and Shneider, 
 16
2001). It was first described by Charcot in 1869 and has a worldwide 
incidence of 1-2 in 100,000 individuals with a lifetime risk factor of 1 in 2,000. 
The number of affected men is approximately 1.6 fold higher than that of 
women. ALS strikes mainly in midlife with an average age of onset between 
50 and 60 years and it is characterised by selective and progressive 
degeneration of motor neurons leading to muscle weakness, wasting and 
spasticity and eventually death within one to five years of onset, mainly 
because of respiratory failure (Brown 1995; Bruijn et al. 2004; Cleveland and 
Rothstein 2001; Rowland and Shneider 2001; Shaw 1999). Early symptoms of 
ALS include fatigue and fasciculations followed by muscle weakness usually 
in the limbs. As a result, in the early stages of the disease, the ALS patients 
experience difficulty in coordination and  in some cases involvement of the 
bulbar muscles leads to slowing of speech or difficulty in swallowing.  
 
Protein aggregation and inclusion body formation are common features of the 
late onset neurodegenerative diseases such as ALS, Alzheimer’s, 
Parkinson’s, Huntington’s and prion disease.  The inclusion bodies in ALS 
consist of ubiquinated protein aggregates mainly seen in the spinal motor 
neurons and motor cortex (Proukakis et al. 2004). In addition, neurofilament 
accumulation is seen in the axons of motor neurons in ALS (reviewed by 
Bruijn et al (Bruijn et al. 2004)). 
 
Approximately10% of ALS cases show familial inheritance that is usually 
autosomal dominant. Of these, 20–25% are mapped to the Cu, Zn-SOD1 
gene on chromosome 21 (Rosen et al., 1993) where over 100 individual 
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mutations have been identified, some of which retain complete enzymatic 
activity (Borchelt et al., 1994; Bowling et al., 1995; Gaudette et al., 2000). In 
the remaining 90% of patients, ALS is sporadic. The clinical manifestation of 
sporadic and familial ALS are very similar, although the age of onset is often 
lower for the familial form of the disease. 
 
Despite intensive research the precise aetiology of the disease remains 
unclear, but transgenic mice over-expressing mutant forms of human SOD1 
have been valuable tools in obtaining insights into the development of the 
disease and in highlighting the cellular functions that are the targets of the 
disease. These mice exhibit an ALS-like phenotype (reviewed by Shibata 
(Shibata 2001)). The presence of intracellular protein aggregates in motor 
neurons is a common feature of all reported cases of human ALS and the 
SOD1-transgenic mouse models. These aggregates stain positive for SOD1 
and ubiquitin in the mouse models and all human SOD1-mediated familial 
ALS. Two main mechanisms have been proposed for the gain of toxicity of 
mutant SOD1 (reviewed by Bruin (Bruijn et al. 2004)). One suggests the 
involvement of Cu and Zn active sites, where a gain of aberrant chemistry in 
mutant SOD1 enzyme damages other proteins and subsequently leads to cell 
death. The second model implicates aggregates as the primary cause of 
motor neuron death. Several mechanisms have been proposed for the 
toxicities of these aggregates, including: aberrant chemistry, loss of protein 
function through co-aggregation with aggregates, depletion of protein folding 
chaperones, dysfunction of the proteasome overwhelmed with undegradable, 
misfolded protein, and inhibition of specific organelle function.  
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 In addition, several studies have highlighted disruptions in axonal transport as 
major contributing factors in motor neuron cell death in ALS (Jablonka et al. 
2004; Rao and Nixon 2003; Williamson and Cleveland 1999). Indeed, defects 
in axonal transport is one of the earliest pathologies observed in SOD1 mice 
(Kieran et al. 2005; Williamson and Cleveland 1999). Moreover, Ligon et al 
have shown that neurotracer transport from muscle to motor neurons is 
impaired in SOD1G93A, and that there is an association of dynein with mutant 
SOD1 aggregates in the motor neurons of these mice (Ligon et al. 2005). 
 
Furthermore, evidence suggest cell specific mechanisms involving motor 
neurons and microglia in disease initiation and progression in human ALS. 
Microglia are activated up on neuronal damage to initiate an inflammatory 
response, termed microgliosis, that affects neighbouring neurons and 
astrocytes. In ALS microgliosis is seen before motor neuron loss and it 
persists as the disease progresses. Biollée et al have recently reported their 
study on the roles of motor neurons and microglia in motor neuron disease 
(Boillee et al. 2006). They used a Cre-lox system to specifically reduce the 
expression of mutant SOD1 either in motor neurons or in the microglia and 
macrophages of mutant-SOD1 transgenic mice. In this study it was shown 
that lowering mutant SOD1 expression within microglia significantly extended 
the survival of the mice, mainly due to a slowing of the disease progression 
after onset. The disease onset and early progression, however, appeared to 
be related to the toxicity of the SOD1 within motor neurons and not microglia. 
These results therefore suggest that mutant SOD1 damage within motor 
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neurons underlies the onset and early progression of the disease, whereas 
progression to the late stages and complete paralysis in these mice is linked 
to the inflammatory response of microglia and the mutant toxicity within these 
cells (Boillee et al. 2006).    
 
Interactions of dynein mutations and mutant SOD1 
The implication of defective dynein in motor neuron degeneration in Loa and 
Cra1 mice, and the evidence linking impaired axonal transport to the 
pathogenesis of motor neuron disease (Hafezparast et al, 2003, Science) 
prompted Kieran et al to study possible interactions between the Loa mutation 
and mutant SOD1 by crossing Loa/+ with SOD1G93A transgenic mice. This 
cross produced double heterozygous (Loa/SOD1G93A), as well as SOD1G93A, 
Loa/+, and wild-type offspring. Parental SOD1G93A and their SOD1G93A pups 
from this cross showed a reduced life span of only 125 days, with disease 
endpoint defined as a loss of the righting reflex and 20% body weight. The 
end-stage for Loa/SOD1G93A double mutants, however, was 160 days of age, 
an increase in lifespan of 28% (p=<0.001). Disease onset was also delayed in 
Loa/SOD1G93A double mutants with a significant delay in the loss of body 
weight (Kieran et al. 2005). This increase in lifespan was not a result of loss of 
toxicity of the mutant SOD1 protein in the double mutants, as when 
Loa/SOD1G93A mice were backcrossed to Loa/+ mice, their SOD1G93A progeny 
had the same phenotype as parental SOD1G93A mice. Nor was this increase in 
lifespan due to a lower amount of SOD1G93A in the double mutants, as 
quantitative western blot analyses on brain and spinal cord samples showed 
that these mice had the same amount of SOD1G93A protein as their SOD1G93A 
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parents (Kieran et al. 2005). Intriguingly, analysis of the retrograde axonal 
transport revealed that defects in this pathway are already present in motor 
neurons of SOD1G93A mice during embryonic development (Kieran et al. 
2005). 
 
Analyses of the nerve and muscle functions and histology of all the genotype 
cohorts established that the Loa/SOD1G93A mice at 120 day of age (late stage 
for SOD1G93A) show a wild type phenotype with regards to muscle force, 
motor unit, and motor neuron survival. In addition, kinetic analysis of 
retrograde axonal transport in motor neurons from wild-type, Loa/+, 
SOD1G93A, and Loa/SOD1G93A E13 embryos showed Loa/+ motor neurons 
displayed a speed profile very similar to that seen in wild-type, suggesting that 
two copies of a mutated dynein heavy chain are required to observe the 
dramatic alteration in retrograde transport previously detected in Loa/Loa 
homozygous mice (Hafezparast et al. 2003; Kieran et al. 2005). Surprisingly, 
the deficit in retrograde transport observed in SOD1G93A motor neurons was 
completely rescued in Loa/SOD1G93A  (Kieran et al. 2005). Similarly, when 
Cra1/+ mice were crossed with SOD1G93A the disease onset was delayed and 
the Cra1/SOD1G93A double mutants lived longer than their SOD1G93A 
littermates (Teuchert et al. 2006).  
 
These results indicate that axonal transport defects play a critical role in motor 
neuron death in SOD1G93A mice. Although the molecular mechanism by which 
dynein mutations induce amelioration of the disease in Loa/SOD1G93A and 
Cra1/SOD1G93A mice is not understood, it is clear that the specific impairment 
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of the neuronal function of cytoplasmic dynein rescues the defect observed in 
SOD1G93A mice and produces a complete recovery of the axonal retrograde 
transport defect. This in turn may be responsible for the delay in disease 
progression and extension in lifespan observed in the double mutants. The 
improvement observed in the axonal retrograde transport in Loa/SOD1G93A 
compared with SOD1G93A mice might have occurred through restoration of the 
distribution of cargo within the motor neurons by rescuing the balance 
between anterograde and retrograde transport. Peripheral axotomy appears 
to be beneficial to survival of motor neurons in SOD1G93A mice (Kong and Xu, 
1999; . Comp. Neurol. 412:373–380). One therefore could argue that the 
amelioration of the disease in Loa/SOD1G93A may be a result of an inhibitory 
effect of the Loa mutation in the transport of negative retrograde signals. 
Alternatively, it is possible that the dynein mutation results in abnormal 
intracellular transport, which in turn may change the localization and/or re-
compartmentalization of mutant SOD1, for instance, interaction of mutant 
SOD1 with organelles such as mitochondria could be altered thus delaying 
cell death. This could be of special interest as the recruitment of mutant SOD1 
to spinal cord mitochondria and sequestration of the anti-apoptotic protein Bcl-
2 in the mitochondria have been suggested to be linked to mutant SOD1-
mediated toxicity (Liu et al., 2004; Pasinelli et al., 2004). Equally, as the 
dynein mutation in Loa is autosomal dominant it is possible that the beneficial 
effects of this mutation in Loa/SOD1G93A mice are the result of differential 
affinities of mutant SOD1 to wild-type and mutant dynein heavy chains with a 
higher affinity towards the Loa allele. The sequestration of the mutant dynein 
by mutant SOD1 would then allow normal dynein to assemble into functional 
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motors restoring the axonal retrograde transport. In support of this notion, 
mutant SOD1 has been reported to colocalize with dynein (Ligon et al, 2005). 
The possible association of mutant SOD1 with the wild type and mutant 
dynein complex is currently under investigation in the authors’ laboratory. 
 
 
CONCLUSIONS 
Due to their size and physiology motor neurons are highly dependent on an 
efficient transport system for the movement of membrane organelles, protein 
complexes, and neuroprotective and signalling molecules along the axons. 
Genetic studies on motor neuron diseases in humans and mouse models 
have provided several lines of evidence linking motor neuron degeneration to 
impaired axonal transport. These studies implicate proteins involved in 
microtubule dynamics and regulation, vesicle-associated membrane proteins, 
and the microtubule associated motor proteins. In addition, there appears to 
be a complex interplay between different components of the axonal transport, 
which if compromised will lead to motor neuron dysfunction or death. 
Furthermore, it is apparent that there is an interaction between mutant SOD1 
and axonal transport and that the modification of this interaction by partial 
inhibition of the dynein function as seen in Loa and Cra1 heterozygotes may 
prove to be beneficial for delaying disease onset and extending the life span. 
Further studies are needed to identify other players involved in these 
interactions and to elucidate the detailed molecular mechanisms that lead to 
motor neuron disease or those that alleviate the disease.    
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Fig. 1. Disease mechanisms in MNDs in relation to the axonal transport system. 
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Table I: Components of axonal transport that are mutated in motor neuron diseases 
Gene/protein Mutation Disorder References 
Microtubule-dynamic 
-associated proteins: 
Tubulin-specific chaperone E (TBCE) W524G Progressive motor neuropathy (pmn) – 
Mouse model 
Bommel et al. 2002;  
Martin et al. 2002 
 
Spastin Various mutations (missense mutations – 
e.g. S362C, C448Y & R499C; nonsense 
mutations – e.g. 1520delT; splice-site 
mutations) 
Spastic paraplegia 4 (SPG4) Hazan et al. 1999 
Vesicle-trafficking 
-associated proteins: 
 
Atlastin 
 
R239C, S259Y and H258R. Spastic paraplegia 3 (SPG3) Zhao et al. 2001 
Amyotrophic lateral sclerosis 2 
(ALS2) 
 
Deletion mutations (e.g. 261delA) and 
single-base substitutions (e.g. C873T) 
Type 3 autosomal recessive amyotrophic 
lateral sclerosis (AR-ALS) 
Hadano et al. 2001 & 2006 
Vacuolar-vesicular protein sorting factor-
54 (VPS54) 
L967Q Wobbler (wr)– Mouse model Duchen and Strich 1968; Mitsumoto et 
al. 1990 & 1993; Schmitt-John et al. 
2005; Quenneville et al. 2006 
Vesicle-associated membrane 
protein/synaptobrevin-associated 
membrane protein B (VAPB) 
 
P56S Spinal muscular atrophy (SMA) and 
Atypical amyotrophic lateral sclerosis 
(ALS8) 
Nishimura et al. 2004 
Spartin 
 
1110delA founder frameshift mutation Troyer syndrome (SPG20) Patel et al. 2002; Proukakis et al. 2004 
CHMP2B (charged multivesicular body 
protein 2B, also known as chromatin-
modifying protein 2B)  
I29V and Q206H  
 
ALS spectrum disorders 
 
Parkinson et al. 2006 
Motor and motor 
-associated proteins: 
Cytoplasmic dynein heavy chain 
(DNCHC1)  
F580Y (Loa), Y1055C (Cra1) Legs at odd angles (Loa) and Cramping 
1 (Cra1) – Mouse  models 
 
Hafezparast et al. 2003 
Kinesin (KIF5A) N256S, Y279C, R280C, A361V Hereditary spastic paraplegia 10 
(SPG10) 
 
Reid et al. 2002;  
Fichera et al. 2004;  
Blair et al. 2006 
Dynactin p150glued G59S Progressive lower motor neuron disease LaMont et al. 2002;  
Munch et al. 2003; Puls et al. 2003 & 
2005 
Other Genes/Proteins: 
Cu, Zn-Superoxide dismutase1 (Cu, Zn-
SOD1) 
Over 100 various mutations Familial ALS in humans and mouse 
models 
Rosen et al. 1993 
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